Journey Medical Corporation released the results of a 16‑week, Phase 1 safety study of its oral rosacea therapy Emrosi (minocycline hydrochloride modified‑release). The trial enrolled 60 healthy adults and found no detectable impact on skin, gastrointestinal, or vaginal microbiota, and the drug was well tolerated with no significant safety issues reported.
The publication adds a peer‑reviewed safety profile to Emrosi’s evidence base, reinforcing its positioning as the lowest‑dose oral minocycline on the market and addressing concerns about antibiotic resistance and microbiome disruption that affect other rosacea treatments.
Emrosi received FDA approval in November 2024 for inflammatory rosacea lesions in adults and was launched in March 2025. The company’s Q3 2025 revenue rose 21% year‑over‑year to $17.6 million, driven by strong demand for the new product. The U.S. rosacea market is estimated at $2.1–$2.27 billion in 2025 and is projected to grow at a CAGR of 6.5–7.1%.
CEO Claude Maraoui said, “We are very pleased to see these important data published in the Journal of Drugs in Dermatology. This peer‑reviewed validation reinforces the differentiated profile of Emrosi as an effective, low‑dose oral treatment for rosacea that does not meaningfully disrupt the normal microbiota or contribute to antibiotic resistance.”
The study’s findings support Journey Medical’s strategy to secure payer coverage and prescriber confidence, bolstering the company’s commercial rollout and positioning Emrosi to capture market share in a competitive rosacea landscape.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.